Britain and America have forged a important commercial pact that will keep no levies on British medicine shipments being sold in the US market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to boost expenditure on medicines through the NHS. This move ensures that duties on these key goods will stay at nothing for a timeframe of 36 months.
This deal comes after earlier threats to dramatically increase tariffs on branded pharmaceutical imports, with figures discussed as high as double the cost.
"This deal with the UK reinforces the international landscape for new treatments and brings much-needed equity to transatlantic medicine commerce," a statement said.
Commercial Importance
Pharmaceuticals constitute one of the UK's largest exports to the America, which is clearly the primary buyer for major UK drugmakers.
Statistics show that in the one-year period to the end of last September, the UK shipped medicines worth £11.1bn to the US. This figure accounted for a significant portion of all goods exports in that span.
"This deal safeguards employment, stimulates funding and paves the way for the UK to establish itself as a worldwide center for biotech and pharma," the Business and Trade Secretary stated.
Detailed UK Commitments
The pact involves several key pledges from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a target to increase total public funding on drugs from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum drug companies must return to the NHS to control costs will be limited at 15%. In the past, repayments exceeded 20%.
Industry Background
The pact comes amid a protracted tension between the pharmaceutical industry and the UK government over spending levels and regulatory access.
This friction were exacerbated by claims that American customers were paying significantly more for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several large manufacturing plans in the UK have been halted or scrapped, while major funding commitments have been pledged toward US facilities.
One official stated that the NHS had to increase expenditure on medicines, noting that its spending on drugs had decreased as a share of its total funding over the previous ten-year period.
